These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 9211494)
121. Post-meal endogenous insulin secretion was significantly lower in head than in body/tail cancer of the pancreas. Shichijo H; Hosaka T; Takewaki F; Sumitani Y; Ishida H; Yasuda K J Med Invest; 2023; 70(3.4):350-354. PubMed ID: 37940518 [TBL] [Abstract][Full Text] [Related]
122. Glucagon, the hyperglycemic agent in pancreatic extracts; a possible factor in certain types of diabetes. PINCUS IJ; RUTMAN JZ AMA Arch Intern Med; 1953 Nov; 92(5):666-77. PubMed ID: 13091483 [No Abstract] [Full Text] [Related]
123. Comparison between changes in serum inorganic phosphorus induced by glucose and glucagon in diabetics. DE VENANZI F Proc Soc Exp Biol Med; 1955 Oct; 90(1):112-5. PubMed ID: 13273370 [No Abstract] [Full Text] [Related]
124. Increased alpha cell to beta cell ratio in patients with pancreatic cancer. Tsuchiya T; Saisho Y; Inaishi J; Sasaki H; Sato M; Nishikawa M; Masugi Y; Yamada T; Itoh H Endocr J; 2022 Dec; 69(12):1407-1414. PubMed ID: 35934795 [TBL] [Abstract][Full Text] [Related]
126. Pancreatic and gut hormones as predictors of new-onset prediabetes after non-necrotising acute pancreatitis: a prospective longitudinal cohort study. Bharmal SH; Kimita W; Ko J; Petrov MS Endocr Connect; 2021 Jun; 10(7):715-724. PubMed ID: 34097643 [TBL] [Abstract][Full Text] [Related]
128. [New-onset diabetes as an early sign of pancreatic cancer]. Ahn J; Lee JK Korean J Gastroenterol; 2013 Nov; 62(5):263-6. PubMed ID: 24262590 [TBL] [Abstract][Full Text] [Related]
129. The polypeptide hormone-derived amyloid forms: nonspecific alterations or signs of abnormal peptide-processing? Westermark P; Johnson KH APMIS; 1988 Jun; 96(6):475-83. PubMed ID: 3293625 [No Abstract] [Full Text] [Related]
130. Hyperglycemia as a risk factor in pancreatic cancer: A nested case-control study using prediagnostic blood glucose levels. Jacobson S; Dahlqvist P; Johansson M; Svensson J; Billing O; Sund M; Franklin O Pancreatology; 2021 May; ():. PubMed ID: 34049822 [TBL] [Abstract][Full Text] [Related]
131. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Smith GD; Egger M; Shipley MJ; Marmot MG Am J Epidemiol; 1992 Nov; 136(9):1110-4. PubMed ID: 1462971 [TBL] [Abstract][Full Text] [Related]
132. The relationship between diabetes and pancreatic cancer. Wang F; Herrington M; Larsson J; Permert J Mol Cancer; 2003 Jan; 2():4. PubMed ID: 12556242 [TBL] [Abstract][Full Text] [Related]
133. Diabetes Type 2 and Pancreatic Cancer: A History Unfolding. De Souza A; Irfan K; Masud F; Saif MW JOP; 2016 Mar; 17(2):144-148. PubMed ID: 29568247 [TBL] [Abstract][Full Text] [Related]
134. Sodium transport in diabetes: two sides to the coin. Lovshin JA; Cherney DZ Nat Rev Nephrol; 2019 Mar; 15(3):125-126. PubMed ID: 30580375 [No Abstract] [Full Text] [Related]
135. Weight Loss With Rising Blood Glucose: Challenges in Distinguishing Conventional Type 2 Diabetes From Pancreatic Cancer-Associated Hyperglycemia. Johannes L; Westcott GP Clin Diabetes; 2023; 41(3):477-480. PubMed ID: 37456104 [No Abstract] [Full Text] [Related]
136. Heparanase contributes to pancreatic carcinoma progression through insulin-dependent glucose uptake. Abecassis A; Hermano E; Yifrach A; Popovtzer A; Meirovitz A; Elkin M Front Cell Dev Biol; 2023; 11():1287084. PubMed ID: 38078007 [TBL] [Abstract][Full Text] [Related]